Reiner L Gentz

Title: Reiner L Gentz: Pioneering Innovations in Protein Research and Disease Treatment

Introduction:

Reiner L Gentz, a distinguished inventor and researcher hailing from Belo Horizonte-MG, BR, has made significant contributions to the field of protein research and the development of novel therapies. With an impressive portfolio of 82 patents to his name, Gentz has dedicated his career to advancing the understanding of Death Domain Containing Receptors (DR) and their implications in disease treatment. Let us delve into some of his most recent patents and his notable affiliations with esteemed organizations.

Latest Patents and Contributions:

1. Death domain containing receptor 4 antibodies and methods:

In this patent, Gentz presents a breakthrough in the development of novel DR4 proteins. DR4 is a member of the tumor necrosis factor (TNF) receptor family associated with apoptosis, or programmed cell death. The patent describes isolated nucleic acid molecules encoding human DR4 proteins and outlines various recombinant methods to produce them. Gentz's invention also includes screening methods to identify agonists and antagonists of DR4 activity, as well as the application of specific antibodies as potential therapeutic agents for diseases associated with abnormal apoptosis levels.

2. Use of DR3 antibodies in the treatment of inflammatory disease:

This patent highlights Gentz's exploration of another DR member, DR3, and its variant, DR3-V1. Like DR4, these proteins are part of the TNF receptor family. Gentz's work involves the identification and characterization of isolated nucleic acid molecules encoding human DR3 and DR3-V1 proteins. The patent further includes the development of recombinant methods to produce these proteins. Additionally, Gentz identifies antibodies and antigen fragments that bind to the proteins, while also proposing screening methods for identifying agonists and antagonists of DR3 and DR3-V1 activity. The aim of this research is to harness DR3 antibodies as potential therapeutic agents for inflammatory diseases.

Influential Organizations and Collaborators:

Throughout his career, Reiner L Gentz has collaborated with renowned institutions and distinguished colleagues. Here are some notable organizations and coworkers associated with his remarkable achievements:

1. Companies:

a. Human Genome Sciences, Inc.: Gentz's association with this highly respected biotechnology company indicates his focus on applying genetic and genomic research to the development of advanced therapies.

b. University of Michigan: This prestigious academic institution has provided Gentz with a platform for cutting-edge research and collaboration, amplifying his contributions to the scientific community.

2. Coworkers:

a. Jian Ni: A collaborator and colleague, Jian Ni has likely played a crucial role alongside Gentz in his research endeavors. Together, their combined expertise has undeniably fueled their innovative breakthroughs.

b. Guo-Liang Yu: Another esteemed coworker, Guo-Liang Yu, has likely contributed significantly to Gentz's research projects, further enhancing the depth and breadth of their collective achievements.

Conclusion:

Reiner L Gentz has established himself as a luminary in the field of protein research and therapeutic development. His extensive patent portfolio, including groundbreaking advancements in the study of DR4 and DR3 proteins, bears testament to his dedication and remarkable expertise. Collaborating with prestigious organizations and talented peers, Gentz continues to push the boundaries of innovation, driving us closer to effective treatments for various diseases associated with aberrant apoptosis and inflammation.